Showing 171-180 of 9443 results for "".
- ctDNA Outperforms MCPyV Antibody Testing for Merkel Cell Carcinoma Surveillancehttps://practicaldermatology.com/news/ctdna-outperforms-mcpyv-antibody-testing-for-merkel-cell-carcinoma-surveillance/2487805/Circulating tumor DNA (ctDNA) may provide a more accurate method for detecting recurrence of Merkel cell carcinoma (MCC) than the currently available Merkel cell polyomavirus (MCPyV) oncoprotein antibody test, according to results from a multicenter US cohort study
- New Data Support 24-Week Abrocitinib Tapering in Controlled ADhttps://practicaldermatology.com/news/new-data-support-24-week-abrocitinib-tapering-in-controlled-ad/2487773/New data published in the Journal of the American Academy of Dermatology suggests tapering abrocitinib may be a feasible strategy for patients with moderate-to-severe atopic dermatitis (AD) who have achieved an adequate clin
- LEO Pharma Reports Positive Phase 2 Pediatric Data for Tralokinumab in Atopic Dermatitishttps://practicaldermatology.com/news/leo-pharma-reports-positive-phase-2-pediatric-data-for-tralokinumab-in-atopic-dermatitis/2487767/LEO Pharma has announced positive topline results from the Phase 2 TRAPEDS-1 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD).
- Report: Dermatology M&A Momentum Sets Sights on Independent Practiceshttps://practicaldermatology.com/news/dermatology-ma-momentum-continues-as-buyers-chase-independent-practices/2487714/Private equity investment in dermatology continues at a rapid pace in 2026, with buyer demand remaining strong despite more than a decade of consolidation across the specialty, according to a new market update from Physician Growth Partners.
- FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With ADhttps://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-005-in-infants-with-atopic-dermatitis/2487703/The US Food and Drug Administration (FDA) anounced that it has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) seeking to expand the indication for ZORYVE (roflumilast) cream 0.05% to include infants aged 3 to 24 months with mild to mode
- Teva Advances Anti-IL-15 Antibody Into Phase 2b for Vitiligohttps://practicaldermatology.com/news/teva-advances-anti-il-15-antibody-into-phase-2b-for-vitiligo/2487696/Teva Pharmaceutical Industries Ltd. has announced plans to advance its investigational anti-interleukin-15 (IL-15) monoclonal antibody (TEV-'408) into a Phase 2b clinical trial for non-segmental vitiligo (NSV) in the fourth quarter of 2026 following encouraging in
- Picankibart Shows Skin Clearance in Plaque Psoriasis: Analysishttps://practicaldermatology.com/news/picankibart-shows-skin-clearance-in-plaque-psoriasis/2487695/A phase III study published in the Journal of the American Academy of Dermatology found that picankibart, an investigational interleukin (IL)-23p19 inhibitor, produced high rates of skin clearance with durable efficacy throu
- Study: Dupilumab Shows Long-Term Disease Control in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/study-dupilumab-shows-long-term-disease-control-in-pediatric-atopic-dermatitis/2487681/Children and adolescents with moderate-to-severe atopic dermatitis (AD) maintained improvements in disease signs and symptoms during 1 year of dupilumab treatment, according to a post hoc analysis of the ongoing phase 3 LIBERTY AD PED-OLE open-label extension study
- Meta-analysis: Topical Ivermectin, Encapsulated BPO Show Strongest Efficacy in Rosaceahttps://practicaldermatology.com/news/topical-ivermectin-encapsulated-benzoyl-peroxide-show-strongest-efficacy-in-rosacea-network-meta-analysis/2487668/A systematic review and network meta-analysis of randomized clinical trials suggests that topical ivermectin and encapsulated benzoyl peroxide (E-BPO) provide greater efficacy than metronidazole for adults with moderate to severe rosacea.
- FDA Grants SKYRIZI Approval to Children With Plaque Psoriasis and PsAhttps://practicaldermatology.com/news/fda-expands-skyrizi-approval-to-include-children-with-plaque-psoriasis-and-psoriatic-arthritis/2487657/The FDA has expanded the indication for SKYRIZI® (risankizumab-rzaa) to include children aged 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, according to an announcement from AbbVie.